Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation.
about
The clinical potential of etrolizumab in ulcerative colitis: hypes and hopesEndothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implicationsMechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitisCurrent status of monoclonal antibody therapy for the treatment of inflammatory bowel disease.Melatonin and ulcerative colitis: evidence, biological mechanisms, and future research.Protective effects of dietary curcumin in mouse model of chemically induced colitis are strain dependent.Posttranslationally modified proteins as mediators of sustained intestinal inflammation.Bilirubin prevents acute DSS-induced colitis by inhibiting leukocyte infiltration and suppressing upregulation of inducible nitric oxide synthase.Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades.Positive role of CCAAT/enhancer-binding protein homologous protein, a transcription factor involved in the endoplasmic reticulum stress response in the development of colitisOverview of biologic therapy for Crohn's disease.Protective role of HSF1 and HSP70 against gastrointestinal diseases.Lancemaside A from Codonopsis lanceolata modulates the inflammatory responses mediated by monocytes and macrophages.The role of p38 mitogen-activated protein kinase in the pathogenesis of inflammatory bowel disease.Candidate mucosal and surrogate biomarkers of inflammatory bowel disease in the era of new technology.The many faces of p38 mitogen-activated protein kinase in progenitor/stem cell differentiation.Immunosuppressive and biologic therapy for ulcerative colitis.Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update.Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target.The role of integrin antagonists in the treatment of inflammatory bowel disease.Orally administered liposomal formulations for colon targeted drug delivery.Alemtuzumab and natalizumab: the monoclonal antibody story continues.Immunotoxicity profile of natalizumab.Anti-inflammatory effect of Euphorbia supina extract in dextran sulfate sodium-induced colitis mice.New and emerging therapies for acute and chronic graft versus host disease.Engineered biomimetic nanovesicles show intrinsic anti-inflammatory properties for the treatment of inflammatory bowel diseases.Protective effect of total alkaloids of Sophora alopecuroides on dextran sulfate sodium-induced chronic colitis.Using affinity capillary electrophoresis and computational models for binding studies of heparinoids with p-selectin and other proteins.A hot water extract of Curcuma longa inhibits adhesion molecule protein expression and monocyte adhesion to TNF-α-stimulated human endothelial cells.Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis.Black tea polyphenol theaflavin suppresses LPS-induced ICAM-1 and VCAM-1 expression via blockage of NF-κB and JNK activation in intestinal epithelial cells.Vascular Endothelial Dysfunction in Inflammatory Bowel Diseases: Pharmacological and Nonpharmacological Targets.
P2860
Q26745725-839795C3-0160-4AB7-B684-2DACFD7D1A44Q26774558-7193A70A-5FED-40B4-9AED-2AF8917113D8Q28292653-4559E449-BE2F-4A16-8B14-319977617F03Q34127277-BB79E468-5C43-4C0A-869D-BBDF5F522451Q34796036-7C2D39C7-4C7A-4774-AC21-8BE56C6D66E7Q35593759-8103CC60-7CC2-4E66-842A-D0261C7ED058Q35607249-D63B7DB1-1A73-4D2D-ACC1-34EA0E97560EQ36297726-125ED9B4-D6D2-4D23-B9C5-F3AE8A26DDD4Q37155166-C7BD9436-F39E-4A8E-973E-C6D1CDBFA52FQ37164215-63353340-3AFF-4CDE-9835-C8F5F2430B04Q37547257-73063A6D-96C2-4E22-BBC7-CDF44350706BQ37658800-975C95DC-4727-4D2B-B81E-32DA589C495AQ37694503-6D84EA8F-3404-4F4D-800F-BF1BEE4A0686Q37940031-5A5244F2-AD51-4B5D-B051-9C4028EF1783Q37951110-CABDC09D-12AD-4FFB-BD75-289384C97678Q38019033-D97D829B-3ACB-4C21-B083-1550C98FD6B5Q38060831-E75DA378-D663-4392-AF04-AD740D01911CQ38068963-BBA54FF1-F02C-412C-B720-7D0D4E9D4E64Q38210630-BE76B221-7335-472F-A6D2-9D934829A51FQ38257410-96CEBDF9-1253-4751-9C1A-583533A85D3FQ40475538-15574CCE-B40C-42A3-8C84-C50909E83759Q40672799-CBB79A00-4950-4299-973F-6D340D5E0FDAQ45979796-CB2DCB8D-02A5-49F8-A8D6-20BB291E3210Q47730321-74B205AD-0ECB-400A-B942-3363A6A0A344Q49238507-40FF91FB-B31F-419B-A246-5E2E3B3A87B0Q49971986-D2BBA23A-92DA-4D4A-92E1-DBA954E1324DQ50514726-BE627A52-6F43-4C98-8927-AFAE2416BEE3Q51113481-8A387426-4558-4A1F-9774-6D704F14AB35Q53525965-3059F8C0-F440-49C1-8BE1-6F57FCBE2C6CQ54273247-C97A8706-5381-406E-BCC0-6E6D6CD823D5Q54624599-EA5D68A3-F37F-4A06-8666-3A564A168C40Q55026430-A7EBC8EB-460E-4D8B-AC61-0C76F5D6B5E6
P2860
Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Adhesion molecules in inflamma ...... ications for gut inflammation.
@ast
Adhesion molecules in inflamma ...... ications for gut inflammation.
@en
type
label
Adhesion molecules in inflamma ...... ications for gut inflammation.
@ast
Adhesion molecules in inflamma ...... ications for gut inflammation.
@en
prefLabel
Adhesion molecules in inflamma ...... ications for gut inflammation.
@ast
Adhesion molecules in inflamma ...... ications for gut inflammation.
@en
P2093
P1476
Adhesion molecules in inflamma ...... lications for gut inflammation
@en
P2093
P304
P356
10.1016/J.DLD.2005.03.013
P50
P577
2005-09-13T00:00:00Z